We create and evaluate new disease control technologies, such as digital contact tracing applications, and apply modelling and machine learning to evaluate epidemic interventions and maximise containment.
We develop and validate point of care and sequenced-based molecular tests, which can be adapted to any pathogen and setting.
We discover, optimise and evaluate new therapeutic targets through the Centre for Medicines Discovery and the Division of Structural Biology, and advance these through academic and commercial partnerships.
We conduct pivotal clinical trials such as the RECOVERY trial and are working to extend international capabilities in platform clinical trials for endemic, epidemic and pandemic infectious diseases.
We design and evaluate new vaccines against outbreak pathogens, such as COVID-19, and develop novel vaccine technologies. We focus on affordability, scalability, and technology transfer.